Citations

Clear

3030 citation(s) found for "Susan, M".

Digital storytelling for hematology education: Interactive thalassemia module for graduate millennial learners
Marshall, Ariela L. , Mann, Susan, Wolanskyj, Alexandra P. , Wolanskyj-Spinner, Alexandra, Marshall, Ariela , Wolanskyj-Spinner, Alexandra P

Mayo Clinic

American Journal of Hematology | November 30, 2018 | Volume: 94 | Issue: 2 | Pages: No page available

10.1002/ajh.25368 | PMID 30499238 Get It

Speaker Gender Representation at the American Society of Anesthesiology Annual Meeting: 2011–2016
Moeschler, Susan M. , Gali, Bhargavi , Goyal, Seeta, Schroeder, Darrell R. , Jacobson, Judy, Habermann, Elizabeth B. , Keegan, Mark T. , Hyder, Joseph A. , Habermann, Elizabeth , Schroeder, Darrell

Mayo Clinic

Anesthesia & Analgesia | November 29, 2018 | Volume: 129 | Issue: 1 | Pages: 301-305

10.1213/ane.0000000000003944 | PMID 30489314 Get It

The American Society of Anesthesiologists (ASA) Annual Meeting is the primary venue for anesthesiologists to present research, share innovations, and build networks. Herein, we describe gender representation for physician speakers at the Annual Meeting relative to the specialty overall. Details of ASA Annual Meeting presentations for individuals and panels were abstracted from the ASA archives for 2011–2016. Observed speaker gender composition was compared to expected composition based on the gender distribution of members of the ASA. There were 5167 speaker slots across 2025 presentations and panels. Of the speaker slots, 3874 were assigned to men and 1293 to women. Speaker slot gender composition was relatively consistent between 2011 and 2016 (annual percentage 22.3%–27.7% women, trend test P = .062). ASA membership composition of women increased slightly over the study period (24%–28%). The overall observed number of women in speaker slots over the study period did not differ significantly from what would be expected based on the ASA membership composition (25.0% observed versus 25.9% expected; P = .153). However, the percentage of single speakers who were women was significantly less than would be expected based on the ASA gender distribution (20.2% observed versus 25.9% expected; P < .001). Interestingly, for panels that included 2–5 anesthesiologists, single-gender panels were more common than would be expected by chance, with all-male panels predominating (all P < .01). The gender composition of speakers at the ASA Annual Meeting largely reflected gender composition within the specialty, although women were not overrepresented at any meeting. The predominance of single-gender panels and underrepresentation of women as single speakers is a potential target to improve gender representation.
Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus
Buckley, Melissa A., Woods, Nicholas T. , Mendoza-Fandiño, Gustavo, Lawrenson, Kate , Hazelett, Dennis J. , Najafabadi, Hamed S. , Gjyshi, Anxhela, Carvalho, Renato S. , Lyra, Paulo C. , Shen, Howard C., Yang, Ally , Earp, Madalene A. , Yoder, Sean J., Chenevix‐Trench, Georgia , Ramus, Susan J. , Phelan, Catherine M., Coetzee, Gerhard A., Hughes, Timothy R. , Sellers, Thomas A. , Goode, Ellen L. , Gayther, Simon A. , Monteiro, Álvaro N.A. , Lu, Karen H. , Goodman, Marc T. , Lissowska, Jolanta , Jakubowska, Anna , Dörk, Thilo , Matsuo, Keitaro , Menon, Usha , Terry, Kathryn L. , Tworoger, Shelley S. , Ekici, Arif B. , Chen, Y. Ann , Eccles, Diana , Teo, Soo‐Hwang , Hein, Alexander , Hillemanns, Peter , Lambrechts, Diether , Jensen, Allan , Brooks‐Wilson, Angela , Sieh, Weiva , Dansonka‐Mieszkowska, Agnieszka , Liang, Dong , Woo, Yin Ling , McNeish, Iain A. , Lambrechts, Diether , Lawrenson, Kate , Hazelett, Dennis J , Najafabadi, Hamed S , Coetzee, Simon G , Ramus, Susan J , Noushmehr, Houtan , Dörk, Thilo , Lambrechts, Diether , McNeish, Iain A , Teo, Soo H , Tworoger, Shelley S , Hein, Alexander , Hillemanns, Peter , Jensen, Allan , Eccles, Diana , Menon, Usha , Monteiro, Alvaro N , Lissowska, Jolanta , Brooks-Wilson, Angela R , Matsuo, Keitaro , Jakubowska, Anna , Lambrechts, Diether , Sieh, Weiva , Ekici, Arif B , Chenevix-Trench, Georgia , Goodman, Marc T , Tyrer, Jonathan P. , Coetzee, Simon G. , Yoder, Sean , Risch, Harvey A. , Noushmehr, Houtan , Pharoah, Paul D.P. , Morais Lyra, Paulo Cilas

Mayo Clinic

Cancer Research | November 28, 2018 | Volume: 79 | Issue: 3 | Pages: 467-481

10.1158/0008-5472.can-17-3864 | PMID 30487138 Get It

Abstract Genome-wide association studies have identified 40 ovarian cancer risk loci. However, the mechanisms underlying these associations remain elusive. In this study, we conducted a two-pronged approach to identify candidate causal SNPs and assess underlying biological mechanisms at chromosome 9p22.2, the first and most statistically significant associated locus for ovarian cancer susceptibility. Three transcriptional regulatory elements with allele-specific effects and a scaffold/matrix attachment region were characterized and, through physical DNA interactions, BNC2 was established as the most likely target gene. We determined the consensus binding sequence for BNC2 in vitro, verified its enrichment in BNC2 ChIP-seq regions, and validated a set of its downstream target genes. Fine-mapping by dense regional genotyping in over 15,000 ovarian cancer cases and 30,000 controls identified SNPs in the scaffold/matrix attachment region as among the most likely causal variants. This study reveals a comprehensive regulatory landscape at 9p22.2 and proposes a likely mechanism of susceptibility to ovarian cancer. Significance: Mapping the 9p22.2 ovarian cancer risk locus identifies BNC2 as an ovarian cancer risk gene. See related commentary by Choi and Brown, p. 439
Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts
Link, Brian K. , Ghesquières, Hervé , Nicolas, Émmanuelle , Thompson, Carrie A. , Traverse‐Glehen, Alexandra , Allmer, Cristine, Ansell, Stephen M. , Salles, Gilles , Link, Brian K , Salles, Gilles A , Sarkozy, Clémentine , Maurer, Matthew J. , Nicolas, Emmanuelle, Feldman, Andrew L. , Slager, Susan L. , Habermann, Thomas M. , Bachy, Emmanuel , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | November 27, 2018 | Volume: 37 | Issue: 2 | Pages: 144-152

10.1200/jco.18.00400 | PMID 30481079 Get It

Purpose Although the life expectancy of patients with follicular lymphoma (FL) has increased, little is known of their causes of death (CODs) in the rituximab era. Patients and Methods We pooled two cohorts of newly diagnosed patients with FL grade 1-3A. Patients were enrolled between 2001 and 2013 in two French referral institutions (N = 734; median follow-up 89 months) and 2002 and 2012 in the University of Iowa and Mayo Clinic Specialized Program of Research Excellence (SPORE; N = 920; median follow-up 84 months). COD was classified as being a result of lymphoma, other malignancy, treatment related, or all other causes. Results Ten-year overall survival was comparable in the French (80%) and US (77%) cohorts. We were able to classify COD in 248 (88%) of 283 decedents. In the overall cohort, lymphoma was the most common COD, with a cumulative incidence of 10.3% at 10 years, followed by treatment-related mortality (3.0%), other malignancy (2.9%), other causes (2.2%), and unknown (3.0%). The 10-year cumulative incidence of death as a result of lymphoma or treatment was higher than death as a result of all other causes for each age group (including patients ≥ 70 years of age at diagnosis [25.4% v 16.6%]) Follicular Lymphoma International Prognostic Index score 3 to 5 (27.4% v 5.2%), but not Follicular Lymphoma International Prognostic Index score 0 to 1 (4.0% v 3.7%); for patients who failed to achieve event-free survival within 24 months from diagnosis (36.1% v 7.0%), but not for patients who achieved event-free survival within 24 months of diagnosis (6.7% v 5.7%); and for patients with a history of transformed FL (45.9% v 4.7%), but not among patients without (8.1% v 6.2%). Overall, 77 of 140 deaths as a result of lymphoma occurred in patients whose FL transformed after diagnosis. Conclusion Despite the improvement in overall survival in patients with FL in the rituximab era, their leading COD remains lymphoma, especially after disease transformation. Treatment-related mortality also represents a concern, which supports the need for less-toxic therapies.
Aspirin, NSAIDs, and Glioma Risk: Original Data from the Glioma International Case–Control Study and a Meta-analysis
Amirian, E. Susan , Ostrom, Quinn T. , Armstrong, Georgina , Lai, Rose , Gu, Xiangjun, Jacobs, Daniel I. , Jalali, Ali , Claus, Elizabeth B. , Barnholtz‐Sloan, Jill S. , Il’yasova, Dora , Schildkraut, Joellen M. , Ali‐Osman, Francis, Sadetzki, Siegal , Jenkins, Robert B. , Bernstein, Jonine L. , Merrell, Ryan , Wrensch, Margaret , Johansen, Christoffer , Houlston, Richard S. , Shete, Sanjay , Melin, Beatrice , Bondy, Melissa L. , Houlston, Richard S , Amos, Christopher I , Barnholtz-Sloan, Jill S , Armstrong, Georgina , Lachance, Daniel Honore , Olson, Sara H. , Amos, Christopher I. , Ostrom, Quinn T

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 27, 2018 | Volume: 28 | Issue: 3 | Pages: 555-562

10.1158/1055-9965.epi-18-0702 | PMID 30482874 Get It

Abstract Background: There have been few studies of sufficient size to address the relationship between glioma risk and the use of aspirin or NSAIDs, and results have been conflicting. The purpose of this study was to examine the associations between glioma and aspirin/NSAID use, and to aggregate these findings with prior published studies using meta-analysis. Methods: The Glioma International Case-Control Study (GICC) consists of 4,533 glioma cases and 4,171 controls recruited from 2010 to 2013. Interviews were conducted using a standardized questionnaire to obtain information on aspirin/NSAID use. We examined history of regular use for ≥6 months and duration-response. Restricted maximum likelihood meta-regression models were used to aggregate site-specific estimates, and to combine GICC estimates with previously published studies. Results: A history of daily aspirin use for ≥6 months was associated with a 38% lower glioma risk, compared with not having a history of daily use [adjusted meta-OR = 0.62; 95% confidence interval (CI), 0.54–0.70]. There was a significant duration-response trend (P = 1.67 × 10−17), with lower ORs for increasing duration of aspirin use. Duration-response trends were not observed for NSAID use. In the meta-analysis aggregating GICC data with five previous studies, there was a marginally significant association between use of aspirin and glioma (mOR = 0.84; 95% CI, 0.70–1.02), but no association for NSAID use. Conclusions: Our study suggests that aspirin may be associated with a reduced risk of glioma. Impact: These results imply that aspirin use may be associated with decreased glioma risk. Further research examining the association between aspirin use and glioma risk is warranted.
Testing a clinical staging model for bipolar disorder using longitudinal life chart data
Markt, Afra van der , Klumpers, Ursula M. H. , Draisma, Stasja , Dols, Annemiek , Nolen, Willem A. , Post, Robert M. , Altshuler, Lori L., Frye, Mark A. , Grunze, Heinz , Keck, Paul E., Suppes, Trisha, Beekman, Aartjan T.F. , Kupka, Ralph , van der Markt, Afra , Grunze, Heinz , McElroy, Susan L.

Mayo Clinic

Bipolar Disorders | November 17, 2018 | Volume: 21 | Issue: 3 | Pages: 228-234

10.1111/bdi.12727 | PMID 30447123 Get It

ObjectiveBipolar disorder has a wide range of clinical manifestations which may progress over time. The aim of this study was to test the applicability of a clinical staging model for bipolar disorder and to gain insight into the nature of the variables influencing progression through consecutive stages.MethodsUsing retrospectively reported longitudinal life chart data of 99 subjects from the Stanley Foundation Bipolar Network Naturalistic Follow‐up Study, the occurrence, duration and timely sequence of stages 2‐4 were determined per month. A multi‐state model was used to calculate progression rates and identify determinants of illness progression. Stages 0, 1 and several other variables were added to the multi‐state model to determine their influence on the progression rates.ResultsFive years after onset of BD (stage 2), 72% reached stage 3 (recurrent episodes) and 21% had reached stage 4 (continuous episodes), of whom 8% recovered back to stage 3. The progression from stage 2 to 3 was increased by a biphasic onset for both the depression‐mania and the mania‐depression course and by male sex.ConclusionsStaging is a useful model to determine illness progression in longitudinal life chart data. Variables influencing transition rates were successfully identified.
TMOD-11. IMAGING BASED INVASION METRIC PREDICTIVE OF RESPONSE TO ABT414 IN ORTHOTOPIC EGFRviii AMPLIFIED PATIENT DERIVED XENOGRAFTS
Marin, Bianca M. , Paulson, Lisa, Kasle, Lauren, Jackson, Pamela , Marin, Bianca M , Massey, Susan Christine , Hawkins‐Daarud, Andrea , Mladek, Ann C. , Sarkaria, Jann N. , Swanson, Kristin R

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi270-vi271

10.1093/neuonc/noy148.1124 Get It

NIMG-16. IMPACT OF SEX DIFFERENCES AND TUMOR LOCATION ON SURVIVAL OUTCOMES IN GLIOBLASTOMA PATIENTS
Lorence, Julia, Johnston, Sandra K. , Ranjbar, Sara , Whitmire, Paula , Rickertsen, Cassandra , León, Gustavo De , Anderies, Barrett J. , White, Haylye, Singleton, Kyle , Hu, Leland , Mitchell, J. Ross , Porter, Alyx B. , Mrugała, Maciej M. , Bendok, Bernard R. , Swanson, Kristin R. , Swanson, Kristin R , Massey, Susan Christine , Leon, Gustavo De, Rubin, Joshua B

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi179-vi179

10.1093/neuonc/noy148.743 Get It

NIMG-12. RADIOGENOMICS ON VENUS AND MARS: IMPACT OF SEX-DIFFERENCES ON MRI AND GENETIC CORRELATIONS IN GLIOBLASTOMA
Hu, Leland , Gaw, Nathan , Yoon, Hyunsoo , Eschbacher, Jennifer , Smith, Kris A. , Karis, John P. , Whitmire, Paula , Singleton, Kyle , Jackson, Pamela , Bendok, Bernard R. , Mitchell, J. Ross , Li, Jing , Baxter, Leslie C. , Nakaji, Peter , Hawkins‐Daarud, Andrea , Massey, Susan Christine , Wu, Teresa , Tran, Nhan L. , Rubin, Joshua B , Swanson, Kristin R

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi178-vi178

10.1093/neuonc/noy148.739 Get It